1. Home
  2. SNPX vs ATCH Comparison

SNPX vs ATCH Comparison

Compare SNPX & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNPX
  • ATCH
  • Stock Information
  • Founded
  • SNPX 2012
  • ATCH 2022
  • Country
  • SNPX United States
  • ATCH United States
  • Employees
  • SNPX N/A
  • ATCH N/A
  • Industry
  • SNPX Medicinal Chemicals and Botanical Products
  • ATCH
  • Sector
  • SNPX Health Care
  • ATCH
  • Exchange
  • SNPX Nasdaq
  • ATCH Nasdaq
  • Market Cap
  • SNPX 3.1M
  • ATCH 3.2M
  • IPO Year
  • SNPX N/A
  • ATCH N/A
  • Fundamental
  • Price
  • SNPX $2.41
  • ATCH $0.21
  • Analyst Decision
  • SNPX Strong Buy
  • ATCH
  • Analyst Count
  • SNPX 1
  • ATCH 0
  • Target Price
  • SNPX $14.00
  • ATCH N/A
  • AVG Volume (30 Days)
  • SNPX 19.8K
  • ATCH 7.7M
  • Earning Date
  • SNPX 05-15-2025
  • ATCH 05-16-2025
  • Dividend Yield
  • SNPX N/A
  • ATCH N/A
  • EPS Growth
  • SNPX N/A
  • ATCH N/A
  • EPS
  • SNPX N/A
  • ATCH 2.67
  • Revenue
  • SNPX N/A
  • ATCH N/A
  • Revenue This Year
  • SNPX N/A
  • ATCH N/A
  • Revenue Next Year
  • SNPX N/A
  • ATCH N/A
  • P/E Ratio
  • SNPX N/A
  • ATCH $0.08
  • Revenue Growth
  • SNPX N/A
  • ATCH N/A
  • 52 Week Low
  • SNPX $1.84
  • ATCH $0.18
  • 52 Week High
  • SNPX $5.05
  • ATCH $83.99
  • Technical
  • Relative Strength Index (RSI)
  • SNPX 49.39
  • ATCH 33.79
  • Support Level
  • SNPX $2.51
  • ATCH $0.19
  • Resistance Level
  • SNPX $2.76
  • ATCH $0.23
  • Average True Range (ATR)
  • SNPX 0.18
  • ATCH 0.02
  • MACD
  • SNPX 0.03
  • ATCH 0.02
  • Stochastic Oscillator
  • SNPX 45.10
  • ATCH 38.18

About SNPX Synaptogenix Inc.

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

About ATCH AtlasClear Holdings Inc. Common Stock

AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.

Share on Social Networks: